Joan Mary Jasien

Joan Mary Jasien

Auto-generated profile, based on publicly available information

Joan Mary Jasien

Department of Pediatrics, Division of Pediatric Neurology and Developmental Medicine Duke University Durham North Carolina USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2018 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
PDF file
KCKathleen M Cardinale
Kathleen M Cardinale
ABAlexandra Bocharnikov
Alexandra Bocharnikov
SHSarah J Hart
Sarah J Hart
JBJane Ann Baker
Jane Ann Baker
CEChristopher Eckstein
Christopher Eckstein
HMHeather Van Mater
Heather Van Mater

10 July 2022 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
JSJessica M. Sun
Jessica M. Sun
LCLaura E. Case
Laura E. Case
CMColleen McLaughlin
Colleen McLaughlin
ABAlicia Burgess
Alicia Burgess
NSNatalie Skergan
Natalie Skergan
JKJoanne Kurtzberg
Joanne Kurtzberg
Aim: To evaluate safety and motor function after treatment with allogeneic umbilical cord blood (AlloCB) or umbilical cord tissue‐derived mesenchymal stromal cells (hCT‐MSC) in children with cerebral palsy (CP).Method: Ninety‐one children (52 males, 39 females; median age 3 years 7 months [range 2–5 years]) with CP due to hypoxic–ischemic encephalopathy, stroke, or periventricular leukomalacia were randomized to three arms: (1) the AlloCB group received 10 × 107 AlloCB total nucleated cells (TNC) per kilogram at baseline (n = 31); (2) the hCT‐MSC group received 2 × 106 hCT‐MSC at baseline, 3 months, and 6 months (n = 28); (3) the natural history control group received 10 × 107 AlloCB TNC per kilogram at 12 months (n = 31). Motor function was assessed with the Gross Motor Function Measure‐66 (GMFM‐66) and Peabody Developmental Motor Scale, Second Edition.Results: Infusions (n = 143) were well tolerated, with eight infusion reactions (three in the AlloCB group, five in hCT‐MSC) and no other safety concerns. At 12 months, the mean differences (95% confidence intervals [CI]) between actual and expected changes in GMFM‐66 score were AlloCB 5.8 points (3.4–8.2), hCT‐MSC 4.3 (2.2–6.4), and natural history 3.1 (1.4–5.0). In exploratory, post hoc analysis, the mean GMFM‐66 score (95% CI) of the hCT‐MSC group was 1.4 points higher than natural history (−1.1 to 4.0; p = 0.27), and the AlloCB group was 3.3 points higher than natural history (0.59–5.93; p = 0.02) after adjustment for baseline Gross Motor Function Classification System level, GMFM‐66 score, and etiology.Interpretation: High‐dose AlloCB is a potential cell therapy for CP and should be further tested in a randomized, blinded, placebo‐controlled trial.What this paper adds: Unrelated donor allogeneic umbilical cord blood (AlloCB) and human umbilical cord tissue‐derived mesenchymal stromal cell infusion is safe in young children with cerebral palsy. Significant changes in motor function were not observed 6 months after treatment. One year later, treatment with AlloCB was associated with greater increases in Gross Motor Function Measure‐66 scores.

27 April 2020 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
GCGeorge T Capone
George T Capone
MSMary Stephens
Mary Stephens
SSStephanie Santoro
Stephanie Santoro
BCBrian Chicoine
Brian Chicoine
PBPeter Bulova
Peter Bulova
DWDown Syndrome Medical Interest Group (DSMIG‐USA) Adult Health Workgroup
Down Syndrome Medical Interest Group (DSMIG‐USA) Adult Health Workgroup

26 October 2018 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
PDF file
JJJoan M Jasien
Joan M Jasien
MBMelanie Bonner
Melanie Bonner
RDRichard D'ALli
Richard D'ALli
LPLyndsey Prange
Lyndsey Prange
MMMelissa Mclean
Melissa Mclean
MMMohamad A Mikati
Mohamad A Mikati

11 April 2022 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
SBScott Barish
Scott Barish
MSMumine Senturk
Mumine Senturk
KSKelly Schoch
Kelly Schoch
AMAmanda L Minogue
Amanda L Minogue
DLDiego Lopergolo
Diego Lopergolo
HBHugo J Bellen
Hugo J Bellen
DROSHA encodes a ribonuclease that is a subunit of the Microprocessor complex and is involved in the first step of microRNA (miRNA) biogenesis. To date, DROSHA has not yet been associated with a Mendelian disease. Here, we describe two individuals with profound intellectual disability, epilepsy, white matter atrophy, microcephaly and dysmorphic features, who carry damaging de novo heterozygous variants in DROSHA. DROSHA is constrained for missense variants and moderately intolerant to loss-of-function (o/e = 0.24). The loss of the fruit fly ortholog drosha causes developmental arrest and death in third instar larvae, a severe reduction in brain size and loss of imaginal discs in the larva. Loss of drosha in eye clones causes small and rough eyes in adult flies. One of the identified DROSHA variants (p.Asp1219Gly) behaves as a strong loss-of-function allele in flies, while another variant (p.Arg1342Trp) is less damaging in our assays. In worms, a knock-in that mimics the p.Asp1219Gly variant at a worm equivalent residue causes loss of miRNA expression and heterochronicity, a phenotype characteristic of the loss of miRNA. Together, our data show that the DROSHA variants found in the individuals presented here are damaging based on functional studies in model organisms and likely underlie the severe phenotype involving the nervous system.

7 February 2020 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
JUJulie Uchitel
Julie Uchitel
EAElie Abdelnour
Elie Abdelnour
ABApril Boggs
April Boggs
LPLyndsey Prange
Lyndsey Prange
MPMilton Pratt
Milton Pratt
MMMohamad A Mikati
Mohamad A Mikati